WealthShield Partners LLC Boosts Holdings in Merck & Co., Inc. (NYSE:MRK)

WealthShield Partners LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,913 shares of the company’s stock after buying an additional 1,987 shares during the quarter. WealthShield Partners LLC’s holdings in Merck & Co., Inc. were worth $2,516,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MRK. Ruedi Wealth Management Inc. boosted its position in shares of Merck & Co., Inc. by 180.2% in the third quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the last quarter. AlphaMark Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $34,000. Valued Wealth Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $42,000. TFO Wealth Partners LLC boosted its position in shares of Merck & Co., Inc. by 108.1% in the third quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after acquiring an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. acquired a new stake in shares of Merck & Co., Inc. in the third quarter worth approximately $50,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on MRK shares. Barclays lifted their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, March 27th. Finally, Truist Financial reissued a “buy” rating and set a $142.00 target price (up from $139.00) on shares of Merck & Co., Inc. in a research report on Thursday, March 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $129.71.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Stock Down 0.3 %

Shares of NYSE:MRK traded down $0.40 during midday trading on Wednesday, reaching $129.95. The company had a trading volume of 4,891,299 shares, compared to its average volume of 8,651,750. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. The stock’s fifty day moving average price is $125.45 and its 200-day moving average price is $113.20. The stock has a market capitalization of $329.12 billion, a P/E ratio of 929.50, a PEG ratio of 0.52 and a beta of 0.38. Merck & Co., Inc. has a one year low of $99.14 and a one year high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same quarter in the previous year, the firm earned $1.62 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts expect that Merck & Co., Inc. will post 8.59 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 2.37%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the transaction, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.